Desmopressin may thus not be the drug of first choice in the treatment of AVWS developing in COVID-19 patients during vvECMO. In case of hemorrhage in this situation, transfusion of …

May 23, 2022 · Veno-venous extracorporeal membrane oxygenation (vvECMO) has become a routine treatment for severe lung failure in specialized centers. Spontaneous bleeding …

Jul 5, 2025 · We present a review of DDAVP and summarize the clinical and laboratory evidence for its use in hemophilia A, von Willebrand disease (VWD), platelet function disorders, uremia, …

Desmopressin acts primarily on V2 receptors, thus eliminating the alpha 1 constriction (and related pressor activity and uterotonic properties) seen with vasopressin (Figure 1).

Jul 5, 2024 · For patients on ECMO support, the requirement for anticoagulation is less stringent. Periodically, significant bleeding and hemorrhage in ECMO patients prevents the use of …

In major bleeding in ECMO patients, we suggest blood transfusion, antico-agulation adjustment, and performing tests to assess AVWS to manage hemostatic and bleeding conditions early.

We performed a retrospective analysis in a single ECMO referral center delineating the risk factors and therapeutic interventions of bleeding during adult ECMO in a total of 59 patients.

Apr 28, 2024 · Therefore, desmopressin may not be the agent of choice to prevent AVWS-related bleeding complications in COVID-19–associated severe ARDS patients supported by ECMO.

Aug 12, 2024 · Bleeding complications are frequently observed in patients undergoing extracorporeal membrane oxygenation and are associated with increased mortality. Due to the …

Jan 19, 2023 · The purpose of this article is to review the evidence for desmopressin in primary hematologic disorders, discuss its mechanism of action and evaluate its utility as a hemostatic …